5 Best Health Sector ETFs to Own Long-Term: IHI vs RSPH vs FBT vs VHT vs IHF 1.7

  • Asset Class: Health Sector

  • Oldest ETF back tested: The Health Care Select Sector SPDR® Fund (XLV)

  • Correlation to U.S. Markets: 0.78

  • Long-Term Performance: 8.43% CAGR

  • S&P 500 Performance: 7.28% CAGR

  • Back test timeframe: January 1999 – June 2023

  • Number of ETFs available in this asset class: 55

  • Number of ETFs in this asset class that are 10-years old or older: 21

XLV vs SPY: January 1999 – June 2023

XLV vs SPY: December 22, 1998 – July 14, 2023

Continue reading “5 Best Health Sector ETFs to Own Long-Term: IHI vs RSPH vs FBT vs VHT vs IHF 1.7”

4 Best Health Sector ETFs to Own Long-Term 1.6

  • Asset Class: Health Sector

  • Oldest ETF back tested: The Health Care Select Sector SPDR® Fund (XLV)

  • Correlation to U.S. Markets: 0.78

  • Long-Term Performance: 8.57% CAGR

  • S&P 500 Performance: 6.79% CAGR

  • Back test timeframe: January 1999 – June 2022

  • Number of ETFs available in this asset class: 52

  • Number of ETFs in this asset class that are 10-years old or older: 21

XLV vs SPY: January 1999 – June 2022

XLV vs SPY: December 22, 1998 – July 8, 2022

Continue reading “4 Best Health Sector ETFs to Own Long-Term 1.6”

4 Best Long-Term Performance Health Sector ETFs 1.5

  • Asset Class: Health Sector

  • Oldest ETF back tested: The Health Care Select Sector SPDR® Fund (XLV)

  • Correlation to U.S. Markets: 0.78

  • Long-Term Performance: 8.81% CAGR

  • S&P 500 Performance: 7.64% CAGR

  • Back test timeframe: January 1999 – June 2021

  • Number of ETFs available in this asset class: 45

  • Number of ETFs in this asset class that are 10-years old or older: 18

XLV vs SPY: January 1999 – June 2021

XLV vs SPY: December 22, 1998 – July 2, 2021

Continue reading “4 Best Long-Term Performance Health Sector ETFs 1.5”

4 Best Long-Term Performance Health Sector ETFs 1.4

  • Asset Class: Health Sector

  • Oldest ETF back tested: The Health Care Select Sector SPDR® Fund (XLV)

  • Long-Term Performance: 8.24% CAGR

  • S&P 500 Performance: 6.55% CAGR

  • Back test timeframe: January 1999 – July 2020

  • Number of ETFs available in this asset class: 41

  • Number of ETFs in this asset class that are 10-years old or older: 17

XLV vs SPY: January 1999 – July 2020

XLV vs SPY: December 22, 1998 – August 7, 2020

Continue reading “4 Best Long-Term Performance Health Sector ETFs 1.4”

4 Best Long-Term Performance Health Sector ETFs 1.3

Is the Health Sector a good place to invest?

The Health Care Select Sector SPDR® Fund (XLV) is the oldest and largest Health Sector ETF available. Its’ inception date was on December 16, 1998.

XLV vs S&P 500 index fund: January 1999 – August 2019

Source: https://www.portfoliovisualizer.com/

XLV vs SPY: December 22, 1998 – September 6, 2019

Source: https://www.koyfin.com/home Continue reading “4 Best Long-Term Performance Health Sector ETFs 1.3”

The Best ETF To Play Biotech (FBT)

Summary

  • Big pharma stocks have underperformed and are likely to continue buying biotech companies for growth.
  • The charts also show large cap biotech companies are underperforming their mid/small cap counterparts.
  • The potential for big pharma and large cap biotech companies looking for needle moving companies points to mid-cap biotech companies being attractive targets for both.
  • Not surprisingly, the biotech ETF with the largest exposure to mid-cap biotech companies has the best performance over the past 1-, 2-, 3- and 5-year periods.

The recently announced deal of Bristol-Myers Squibb (BMY) acquiring Celgene (CELG) got me thinking about biotech & big pharma stocks. The following chart perfectly sums up why I believe big pharma will continue to be acquirers of large-cap biotech companies and small/mid cap companies. Slowing growth due to generic competition and increased scrutiny of drug prices has caused shares of big pharma companies to underperform biotechs and the overall healthcare sector. As you can see below, big pharma as represented by the SPDR S&P Pharmaceuticals ETF (XPH), has gone nowhere since the beginning of 2016, while biotech as represented by the SPDR Biotech ETF (XBI) is up substantially, as is the Health Care Select Sector SPDR ETF (XLV). Simply put, given this vast underperformance, I expect big pharma to go on a spending spree to buy future growth and I will be detailing the current ETF options available in the biotech sector.

Continue reading at Seeking Alpha right here:  https://seekingalpha.com/article/4238204-best-etf-play-biotech

Best Long-Term Performance Health Sector ETFs 1.2

  • The oldest Health Sector ETF has outperformed an S&P 500 index fund by 1.90% CAGR over the last 19 years. This Health Sector ETF has also experienced less volatility than an S&P 500 index fund.
  • There are currently 35 ETFs in the Morningstar Category called Health. 16 of these funds are 10 years old or older.
  • The top performing Health Sector ETF has outperformed an S&P 500 index fund by 8.98% CAGR over the last 12 years.

Health Care Select Sector SPDR® Fund (XLV) vs S&P 500 index fund: January 1999 – September 2018

Source: https://www.portfoliovisualizer.com/

Continue reading “Best Long-Term Performance Health Sector ETFs 1.2”

Sold Some Of Our Biotech Equity Holdings Today (FBT)

We sold some of our Biotech holdings today. I don’t currently see any problems in this is industry or this particular ETF at this time. We only sold to use the funds in another endeavor. Price paid $89.36, price sold $117.12. The First Trust NYSE Arca Biotechnology Index Fund (FBT : $FBT) is still a great fund and I still recommend it to other investors. I wrote about FBT back in January 2017 and updated the charts in the article in May 2017 right here: Discovering Value in Growth Stock Funds: Biotech ETFs

Are Biotech Funds Buys Once Again?

Are Biotech Funds Buys Once Again?

While a number of market industries were fearful of a Trump Presidency, nowhere was the concern more prevalent than in the biotech and drug segment. After all, Trump came out several times against the pricing practices in the drug market, vowing to do something to make this a more affordable area…. (Read full article at Zacks.)

Trimmed some more fat off our Biotech Equities today (FBT)

WordPress › Error

There has been a critical error on this website.

Learn more about troubleshooting WordPress.